At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of ENDEAVOR, a randomised, open-label, phase 3 trial comparing carfilzomib plus dexamethasone versus bortezomib plus dexamethasone in patients with relapsed multiple myeloma.
